Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments
- Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision companion diagnostics for chimeric antigen receptor (CAR)-T cell therapies, the company announced. LDHI is a hematology research institute based in Beijing developing precision diagnostics based on personalized genomic, proteomic, transcriptomic and metabolomic platforms.
- 05/18/2022
|
Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials
- Avalon GloboCare Corp (NASDAQ:AVCO) has revealed that is has filed 16 patent applications related to novel cellular therapies and related technologies as the company moves towards clinical trials. The company said the patents were filed with US Patent and Trademark Office, the China National Trademark Office, and under the Patent Cooperation Treaty covering 36 countries.
- 04/27/2022
|
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
- Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
- 02/14/2022
|
Avalon GloboCare expands its cellular immuno-oncology program with addition of Chimeric Antigen Receptor-Natural Killer cell therapies
- Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) cell therapies. Natural killer (NK) cells constitute an important component of the immune system.
- 02/14/2022
|
Avalon GloboCare well poised for growth this year; intended SenlangBio acquisition terminated
- Avalon GloboCare Corp (NASDAQ:AVCO) told investors it was 'well positioned' to execute on its growth strategy this year as the company highlighted it had partnered with world-renowned research centers and universities. In a year-end update, the clinical stage, cell therapy company noted its new collaboration with the University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes.
- 01/04/2022
|
Avalon GloboCare advances its AI-enhanced protein design technology for cellular therapy development in collaboration with MIT
- Avalon GloboCare Corp (NASDAQ:AVCO) announced that it has further advanced its research to accurately predict the 3-dimensional structures of protein receptors for potential use as cellular therapy targets, in partnership with the Massachusetts Institute of Technology (MIT). The Toronto-based company collaborated with the institute to combine its artificial intelligence (AI)-enhanced protein design ‘QTY Code' technology with Google's AlphaFold2, a DeepMind AI program developed to predict 3D protein structures of previously difficult to work with drug targets.
- 12/09/2021
|
Avalon GloboCare successfully co-develops novel platform of S-layer coated emulsome technology for next-generation drug delivery and cellular immunotherapy
- Avalon GloboCare Corp. has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy.
- 10/14/2021
|
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
- FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.
- 10/14/2021
|
Avalon GloboCare announces co-development of in-silico system to expand its ability to design and produce novel cell membrane proteins
- Avalon GloboCare Corp. has announced the co-development of a novel, cell-free, in-silico system to facilitate its drug development efforts.
- 10/07/2021
|
Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
- Image Provided by Pixabay Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in patients suffering from COVID-19. The condition is an inflammatory syndrome triggered by hyperactivation of immune cells that can significantly impact the patient's chances of making a full recovery or surviving the infection at all.
- 10/07/2021
|
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
- FREEHOLD, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced co-development of a novel, cell-free, in-silico system to facilitate the Company's drug development efforts, together with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. A study of the new technology was featured in the September 2021 issue of Membranes, an international, peer-reviewed journal.
- 10/07/2021
|
Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment
- Image Provided by Pexels With a compound annual growth rate (CAGR) of 34.2%, the global CAR-T cell therapy market is projected to hit $15.4 billion by 2028. This hypergrowth is largely driven by the incredible promise of CAR-T cell therapy as an effective, lasting way to fight cancer.
- 09/30/2021
|
AVALON GLOBOCARE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Avalon GloboCare Corp. - AVCO
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hebei Senlang Biotechnology Co. Ltd. to Avalon GloboCare Corp. (“the Company”) (NasdaqCM: AVCO). Under the terms of the proposed transaction, Avalon will reportedly issue 81 million shares of its common stock to acquire SenlangBio. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-avco/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
- 09/08/2021
|
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
- PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ: AVCO) aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks. Cancer immunotherapy, which stimulates and trains a patient's own immune system to target and kill tumors while leaving healthy cells intact, is an effective treatment for many cancer patients.
- 08/04/2021
|
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
- PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ: AVCO) aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks.
- 08/04/2021
|
Avalon GloboCare, UPMC Hillman and University of Pittsburgh to develop new cancer immunotherapy
- Avalon GloboCare Corp, UPMC Hillman Cancer Center, and the University of Pittsburgh said they have forged a collaboration to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring powerful treatments to cancer patients “within days instead of weeks.” Cancer immunotherapy, which stimulates and trains a patient's own immune system to target and kill tumors while leaving healthy cells intact, is an effective treatment for many cancer patients.
- 08/02/2021
|
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Avalon GloboCare Corp. - AVCO
- NEW YORK, July 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Avalon GloboCare Corp. ("AVCO" or the "Company") (AVCO) relating to its proposed merger with Hebei Senlang Biotechnology Co. Ltd. The investigation focuses on whether Avalon GloboCare Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
- 07/16/2021
|
Avalon GloboCare says its planned acquisition target SenlangBio starts first-in-human clinical trial for recurrent brain cancer
- Avalon GloboCare Corp (NASDAQ:AVCO) said its planned acquisition target, SenlangBio, has initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor (CAR) T-cell therapy for recurrent glioblastoma. Glioblastoma is the most common type of primary brain tumor -- a devastating and aggressive cancer with few treatment options.
- 07/01/2021
|
Avalon GloboCare says SenlangBio will enhance its capabilities in cell and gene therapy
- Avalon GloboCare Corp (NASDAQ:AVCO) told shareholders that its acquisition of Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing, clinical development programs, and pre-clinical research, will enhance the company's capabilities in cell and gene therapy. The deal, which was announced June 13, 2021, will see Avalon enter into a share purchase agreement for an aggregate of 81 million shares of its common stock, valued at US$0.0001 per share.
- 06/28/2021
|
Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
- Previously Announced Execution of Definitive Agreement to Acquire SenlangBio
- 06/28/2021
|
Avalon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Avalon GloboCare Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AVCO
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Avalon GloboCare Corp. (NASDAQ: AVCO) and Hebei Senlang Biotechnology Co. Ltd is fair to Avalon shareholders. In connection with the transaction, Avalon will issue 81 million shares of its common stock to acquire SenlangBio. Halper Sadeh encourages Avalon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (
- 06/14/2021
|
Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights
- Avalon GloboCare Corp (NASDAQ: AVCO) has agreed to acquire Hebei Senlang Biotechnology, dubbed SenlangBio, a China-based cell therapy company, in an all-stock transaction. In connection with the transaction, Avalon will issue 81 million shares of its common stock.
- 06/14/2021
|
Avalon GloboCare inks definitive agreement to acquire Chinese cell therapy company Senlang Biotechnology
- Avalon GloboCare Corp (NASDAQ:AVCO) has reached a definitive agreement to acquire Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing scale, breadth and depth of clinical development programs, and pre-clinical research. SenlangBio's core technology platforms include chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR Gamma Delta T-cells (CAR-γδT), and armored tumor infiltrating lymphocytes (armTILs), the company said.
- 06/14/2021
|
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
- SenlangBio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδ T cell therapy candidates targeting hematologic malignancies and solid tumors
- 06/14/2021
|
Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
- FREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Noble Capital Markets Investor Forum during the 16th Annual World Stem Cell Summit to be held virtually on June 14-18, 2021.
- 06/11/2021
|
Avalon GloboCare says CEO to present S-layer nanotechnology, QTY code platforms at 2021 World Stem Cell Summit
- Avalon GloboCare Corp (NASDAQ:AVCO) has announced that its CEO David Jin will chair a session on “Hot Topics and Future Trends” at the 2021 World Stem Cell Summit, held virtually June 14-18, 2021. The session will feature Avalon's two breakthrough technology platforms, S-layer nanotechnology and QTY code, in co-development with the Massachusetts Institute of Technology (MIT) and the University of Natural Resources and Life Sciences in Vienna (BOKU), respectively.
- 06/08/2021
|
Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus
- Specializes in developing cell-based technologies and manages stem-cell banks and clinical laboratories Creates proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology Also helping in the fight against coronavirus (COVID-19) What Avalon GloboCare does: Avalon GloboCare Corp (NASDAQ:AVCO) specializes in developing cell-based technologies but is also involved in the management of stem-cell banks and clinical laboratories and the fight against coronavirus (COVID-19). Via its two platforms, Avalon Cell and Avalon Rehab, the company develops proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology.
- 04/20/2021
|
Avalon GloboCare to partner with University of Pittsburgh Medical Center Hillman Cancer Center to develop therapies using FLASH-CAR tech
- Avalon GloboCare Corp (NASDAQ:AVCO) said it will collaborate with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the company's AVA-011 therapy and other RNA-based candidates. AVA-011 targets tumor antigens on cancer cells and is being developed for patients with relapsed/refractory B-cell lymphoblastic leukemia and non-Hodgkin's lymphoma ahead of the first human clinical trials.
- 03/29/2021
|
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Platform
- FREEHOLD, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces entering into a collaboration agreement with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the clinical development and production of Avalon's next-generation, chimeric antigen receptor (CAR) therapies using FLASH CAR™ technology.
- 03/29/2021
|
Avalon GloboCare expands its MIT co-development research program to fight cancer spread
- Avalon GloboCare Corp (NASDAQ:AVCO) has said it is expanding its co-development research program with the Massachusetts Institute of Technology (MIT), involving the use of CRISPR-based genome editing and QTY protein design technology to potentially treat and prevent cancer metastasis – the spreading of cancer cells from the initial tumor site to surrounding tissues and other organs. The company noted that its collaboration with MIT on the QTY code has already successfully generated a prototype device to soak up the excess chemokines and cytokines produced in the body that lead to a potentially fatal ‘cytokine storm,' which can occur in patients with coronavirus (COVID-19) and in cancer patients being treated with CAR T-cell therapy.
- 03/22/2021
|
Avalon GloboCare seeking to tap the power of cells to fight cancer and coronavirus
- Specializes in developing cell-based technologies and manages stem-cell banks and clinical laboratories Creates proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology Also helping in the fight against coronavirus (COVID-19) What Avalon GloboCare does: Avalon GloboCare Corp (NASDAQ:AVCO) specializes in developing cell-based technologies but is also involved in the management of stem-cell banks and clinical laboratories and the fight against coronavirus (COVID-19). Via its two platforms, Avalon Cell and Avalon Rehab, the company develops proprietary diagnostic and therapeutic products leveraging regenerative medicine and exosome technology.
- 03/15/2021
|
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular Therapeutics
- FREEHOLD, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced an update on its partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria. The collaboration brings together BOKU's S-layer nanotechnology with Avalon's expertise in biomanufacturing, cell therapy engineering, and clinical development.
- 12/30/2020
|
Contrasting Waste Connections (NYSE:WCN) and Avalon (NYSE:AWX)
- Waste Connections (NYSE:WCN) and Avalon (NYSE:AWX) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Volatility and Risk Waste Connections has a beta of 0.47, suggesting that its stock price is […]
- 10/14/2020
|
SandRidge Permian Trust Confirms Receipt of Unsolicited Exchange Offer and Separate Sale of Assets by Sponsor
- SANDRIDGE PERMIAN TRUST (OTC Pink: PERS) today confirmed that it has received notice that SRPT Acquisition, LLC, a wholly owned subsidiary of PEDEVCO
- 10/14/2020
|
Artificial Grass Turf Market to Reach USD 1.49 Billion by 2024, Avalon BV and CoCreation Grass Corp. Emerge as Key Contributors to Growth | Technavio
- The Global Artificial Grass Turf Market will grow by USD 1.49 bn during 2020-2024
- 10/09/2020
|
'The more complaints we got, the better' – how Spitting Image redefined satire
- Roy Hattersley, Ian Hislop and other writers, actors and puppeteers reveal what made the original show a success and why we need it now more than ever
- 10/01/2020
|
The Latest: India's daily cases continue downward trend
- India has registered 88,600 new confirmed coronavirus cases in the past 24 hours in a declining trend with recoveries exceeding daily infections
- 09/27/2020
|
The Latest: Hawaii to take over veterans home where 26 died
- A state-owned health care organization in Hawaii will take over a veterans care home where 26 residents have died of the coronavirus
- 09/26/2020
|
Financial Survey: Avalon (NYSE:AWX) vs. Advanced Disposal Services (NYSE:ADSW)
- Advanced Disposal Services (NYSE:ADSW) and Avalon (NYSE:AWX) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership. Analyst Ratings This is a summary of recent ratings and price targets for Advanced Disposal […]
- 09/20/2020
|
Why Avalon Globocare's Stock Is Trading Higher Today
- * Avalon Globocare (NASDAQ: AVCO) shares are trading higher on Wednesday after the company announced the commercialization and distribution agreement with Cellex for the coronavirus antibody rapid test kit. * Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promote and empower high impact, transformative biotechnology, and their clinical applications, and healthcare facility management. It has two reportable segments: real property operating segment which is the key revenue driver; medical-related consulting services segment; and development services and sales of developed products segment. * The company focuses on the diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders. * Avalon Globocare's stock was trading up 14.82% to $1.82 per share at the time of publication on Wednesday. The stock has a 52-week high of $2.65 and a 52-week low of 50 cents.See more from Benzinga * Why FBL Financial's Stock Is Trading Higher Today * Why Cinemark's Stock Is Trading Lower Today * Why Roku's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/19/2020
|
Avalon GloboCare Announces Commercialization and Distribution Agreement with Cellex for COVID-19 Antibody Rapid Test Kit
- In anticipation of high demand, Avalon is working with Cellex to source manufacturing facilities and develop next generation COVID-19 testing kitsFREEHOLD, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that the Company has entered into a commercialization partnership agreement with North Carolina-based Cellex, Inc., whereby Avalon has been awarded distribution rights to market Cellex’s COVID-19 antibody-based rapid test kit, which has been granted U.S. FDA Emergency Use Authorization (EUA). Avalon is also working with Cellex to source manufacturing facilities and to develop next generation COVID-19 detection kits. This agreement allows Avalon to initiate distribution and marketing of the U.S. FDA EUA registered tests to the Company’s designated network of channel partners and distributor affiliates, both in the U.S. and internationally. These rapid test kits are highly accurate and are able to detect IgG and IgM antibodies specific to the SARS-CoV-2 that causes COVID-19 in serum, plasma, and whole blood within 15 minutes. “The rapid spread of COVID-19 around the world has driven demand for SARS-CoV-2 detection, especially for rapid antibody testing,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “The global COVID-19 rapid test kit market is expected to reach $3.52 billion by the end of 2020. We look forward to leveraging our international network of strategic partners to commercialize this differentiated COVID-19 rapid test. At the same time, we are continuing our efforts to rapidly advance technologies to help combat the international COVID-19 pandemic through our ongoing programs in S-layer mucosal vaccine development and the AVA-Trap™ therapeutic and blood filtration system to combat cytokine storms.”About Avalon GloboCare Corp.Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEXTM), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.Forward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.Contact Information: Avalon GloboCare Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728 PR@Avalon-GloboCare.comInvestor Relations: Crescendo Communications, LLC Tel: (212) 671-1020 Ext. 304 avco@crescendo-ir.com
- 08/19/2020
|
Avalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine Storms
- * Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on Avalon’s proprietary AVA-Trap™ technology * Reflects advancements to Avalon’s AVA-Trap™ blood filtration system designed to rid the body of cytokines unleashed during the “cytokine storm” and acute respiratory distress syndrome (ARDS) in COVID-19 patients, as well as cancer patients treated with CAR T-cell therapy and other patients that require rapid removal of cytokines from the body * The expanded patent application combines two novel technologies—S-layers and a protein design code tool—for a decoy cytokine receptor system to filter out pro-inflammatory cytokine levels in the blood in those experiencing cytokine stormFREEHOLD, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that Avalon has expanded and filed two provisional patents with the U.S. Patent and Trademark Office outlining compositions and methods of developing a decoy cytokine receptor-based filter system to treat “cytokine storms.” These provisional patent applications are direct results of recent advancements related to Avalon’s AVA-Trap™ therapeutic program. The technology utilizes cytokine receptor–Fc-fusion proteins to potentially serve as an antibody-like decoy to dampen the excessive cytokine release that occurs during hyper-activation of the immune system—a life-threatening condition called “cytokine storm” that can cause multi-organ failure and death. Patients infected with the SARS-CoV-2 virus that causes COVID-19 are susceptible to developing cytokine storms, which occur when the immune system suddenly produces high levels of inflammatory proteins called cytokines that concentrate in the blood. The extracorporeal hemo-purifier device is designed to provide potential treatment for patients experiencing cytokine storms induced by COVID-19, hepatitis, HIV, influenza, graft-versus-host disease, and cytokine release syndrome associated with CAR-T cell therapy.The expanded patent application was jointly filed with Professor Shuguang Zhang of the Massachusetts Institute of Technology (MIT) Media Lab, and Professor Uwe Sleytr, a full member of the Austrian Academy of Sciences and pioneer of applied surface layer (“S-layer”) nanotechnology.The application combines Avalon’s AVA-Trap™ program with two innovative technologies. The first is the QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT. This technology platform can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be used in many clinical applications. The second technology is applied S-layer nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. Coating of S-layers on solid surfaces can greatly enhance the binding orientation and efficiency of targeted ligand proteins that are directed to bind to, and capture, molecules of choice in the blood.Together, Avalon is developing these unique technologies to advance an extracorporeal hemodialysis and hemo-purification device consisting of membrane protein receptors for specific cytokines coated onto an S-layer-based matrix that can be used to specifically filter out cytokines responsible for a “cytokine storms” in patients experiencing this immune system attack on the body, including patients with COVID-19.While non-specific blood filtration systems exist, the clinical AVA-Trap™ blood filtration system would specifically target cytokine storm-causing proteins, allowing the detection and recovery of cytokines—and serving as a potential clinical therapy as well as a diagnostic tool. Importantly, it is the Company’s goal to develop a filtration system that can be customized to trap only specific molecules.“We are grateful for our strong scientific partnerships that enabled the rapid speed with which we are developing this novel clinical tool,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This medical device holds enormous promise as it directly addresses a leading cause of mortality for patients with illnesses that make them vulnerable to the damaging effects of a cytokine storm,” added Dr. Jin.About Avalon GloboCare Corp.Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.Forward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.Contact Information: Avalon GloboCare Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728 PR@Avalon-GloboCare.comInvestor Relations: Crescendo Communications, LLC Tel: (212) 671-1020 Ext. 304 avco@crescendo-ir.com
- 08/12/2020
|
Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19
- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate.
- 07/13/2020
|
Here's What Avalon GloboCare Corp.'s (NASDAQ:AVCO) Shareholder Ownership Structure Looks Like
- A look at the shareholders of Avalon GloboCare Corp. (NASDAQ:AVCO) can tell us which group is most powerful...
- 07/03/2020
|
Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001
- - Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR).
- 06/29/2020
|
Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate
- - Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B..
- 06/25/2020
|
Eminent Member of the Austrian Academy of Sciences, Professor Uwe B. Sleytr, Joins Avalon GloboCare's Scientific and Clinical Advisory Board
- Avalon GloboCare Corp. (AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Professor Uwe B. Sleytr to its Scientific and Clinical Advisory Board. Professor Uwe B. Sleytr is a world-renowned scientist and pioneer in nanobiotechnology.
- 06/16/2020
|
Gene editing turns immune cells into more potent cancer killers
- University of California, San Diego researchers edited a gene called CISH from the immune system's natural killer (NK) cells, freeing up the signaling of cytokines—molecules that direct immune cells to destroy invaders. The edited NK cells cleared leukemia in mouse models and could prove promising as an off-the-shelf cell therapy for some cancers, the researchers said.
- 06/15/2020
|
Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR™ Technology
- FREEHOLD, N.J., June 11, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it.
- 06/11/2020
|
At 23.5% CAGR, Regenerative Medicine Market Size, Growth Research Analysis and Share to reach around US $19000 million by 2024
- Jun 08, 2020 (Market Insight Reports) --
Selbyville, Delaware According to Market Study Report, Provides A Detailed Overview Of Regenerative Medicine Market...
- 06/08/2020
|
Avalon GloboCare Announces Diagnostic Platform for Point-of-Care Rapid Detection of COVID-19 (SARS-CoV-2) and Its Clinically Relevant Mutation Strains
- Entered Into Strategic Partnership with GensKey Medical Technology Co. Ltd. to Co-Develop and Commercialize Point-of-Care Antibody-Based IgG/IgM and PCR-Based SARS-CoV-2.
- 06/08/2020
|
Insights on Global Regenerative Medicine Partnering Terms and Agreements (2014 to 2020) - ResearchAndMarkets.com
|
Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers
- RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of.
- 05/08/2020
|
Columbia Care Reports Preliminary First Quarter 2020 Results and Provides Operational Update
- Columbia Care, Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) is providing an operational update along with
- 05/07/2020
|
Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX™ Product Development and Commercialization
- Focused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product DevelopmentSigned Three-Way Material Transfer Agreement.
- 04/28/2020
|
Avalon Globocare Corp (NASDAQ:AVCO) Short Interest Down 8.8% in March
- Avalon Globocare Corp (NASDAQ:AVCO) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 779,300 shares, a decline of 8.8% from the March 15th total of 854,100 shares. Based on an average daily trading volume, of 160,800 shares, the days-to-cover ratio is presently 4.8 […]
- 04/22/2020
|
EXEL, TNK among premarket gainers
- Avalon GloboCare (NASDAQ:AVCO) +44% on advancing immunotherapeutic program towards combatting cytokine storm associated with COVID-19 lung damage and mortality.Safe-T Group Ltd (NASDAQ:SFET) +41% on r
- 04/20/2020
|
Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality
- Completed Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as “Molecular Mop” to Remove Excessive Cytokines (“Cytokine Storm”) Related to Coronavirus.
- 04/20/2020
|
Specialized Proteins May Halt the Severe Cytokine Storms Seen in COVID-19 Patients
- Team designs antibody-like receptor proteins that can bind to cytokines, as possible strategy for treating coronavirus and other infections. One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also ca
- 04/19/2020
|
Muere por coronavirus Allen Daviau, el director de fotografía del Spielberg más íntimo
- El cineasta, responsable de la imagen de ‘E.T., el extraterrestre’ o ‘El imperio del sol’, ha fallecido en la residencia de la Fundación de Cine y Televisión, donde según ‘The Hollywood Reporter’ ya han perdido la vida cuatro personas por la covid-19
- 04/17/2020
|
Insider Purchasing Could Indicate A Bottom In These Stocks - Weekly Update (04/02/20 - 04/08/20)
- The market gained almost 9% in the week of 2 April until 8 April. Investors with much cash on hand can keep cautiously buying high-quality stocks. Mimicking ins
- 04/10/2020
|
Avalon GloboCare to Present at the 32nd Annual ROTH Conference on March 16, 2020
- FREEHOLD, N.J., Feb. 24, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it.
- 02/24/2020
|
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Cellular Therapy in the Asia Pacific Region” Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASTCT and CIBMTR Tandem Meeting 2020
- FREEHOLD, N.J., Feb. 04, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that its.
- 02/04/2020
|
Are Insiders Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Stock?
- It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- 01/14/2020
|
Avalon GloboCare to Present at Biotech Showcase™ 2020
- FREEHOLD, N.J., Jan. 06, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced its Chief.
- 01/06/2020
|
Avalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular Medicines
- Forms Major Regional Hub in China for CellTech IndustryPartnership Delivers Synergy of Infrastructural Resources for Clinical Development and Bioprocessing Technologies in.
- 12/20/2019
|
Avalon GloboCare to Present at the 12th Annual LD Micro Main Event on December 10th
- FREEHOLD, NJ / ACCESSWIRE / November 20, 2019 / Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that management will present ...
- 11/20/2019
|
Can We See Significant Insider Ownership On The Avalon GloboCare Corp. (NASDAQ:AVCO) Share Register?
- The big shareholder groups in Avalon GloboCare Corp. (NASDAQ:AVCO) have power over the company. Large companies...
- 11/15/2019
|
Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants
- FREEHOLD, N.J., Oct. 21, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced plans to.
- 10/21/2019
|
Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies
- FREEHOLD, N.J., Sept. 19, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has.
- 09/19/2019
|
Avalon GloboCare Announces $20 Million Credit Facility Provided by Company Chairman
- Avalon GloboCare Corp. (AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced it has secured a $20 million credit facility provided by the Company’s Chairman, Daniel Lu. The unsecured credit facility bears interest at a rate of 5% and provides for maturity on drawn loans 36 months after funding. The credit facility will be used to accelerate the Company’s ongoing research and development programs, clinical studies, as well as commercial strategies.
- 09/03/2019
|
MULTIMEDIA UPDATE: Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines
- FREEHOLD, N.J., July 22, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced.
- 07/23/2019
|
Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines
- FREEHOLD, N.J., July 22, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced.
- 07/22/2019
|
Avalon GloboCare Provides Updates on its Lead Clinical Programs in CAR-T Therapy and Exosome-Based Regenerative Therapeutics
- CD19 CAR-T candidate, AVA-001, has entered first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in July.
- 07/15/2019
|
18 Stocks Joining The Russell Indices
- The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
- 06/28/2019
|
Avalon GloboCare Appoints Dr. Yen-Michael Sheng Hsu, Founding Director of cGMP Cellular Therapy Facility at Weill Cornell Medicine, to its Scientific and Clinical Advisory Board
- FREEHOLD, N.J., June 26, 2019 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company.
- 06/26/2019
|
Avalon Globocare (AVCO) Stock: The Wolf of Wall Street?
- Low-priced biotech stocks are often targets of pump-and-dump manipulation scams or other activity designed to make money for a select few, not you (think
- 01/25/2019
|
2nd International Translational and Regenerative Medicine Conference -
- ITMC-2019 Conference Valencia, Spain
- 09/11/2018
|
